AB-8939 for gata2 deficiency

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 27 Jan 2022: Trial registered, NCT05211570
  2. 1 Jun 2022: Trial started, NCT05211570

The trials

NCT05211570: AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

State
Under way
Phase
Phase 1 and Phase 2
People
78 planned
Started
1 Jun 2022
Primary completion
Aug 2026
Arms
AB8939
Results
None posted
  1. 27 Jan 2022: Trial registered
  2. 1 Jun 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.